Rebalance’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$682K Buy
569
+5
+0.9% +$5.11K 0.04% 72
2026
Q1
$519K Sell
564
-20
-3% -$20.3K 0.03% 74
2025
Q4
$628K Buy
584
+1
+0.2% +$956 0.04% 71
2025
Q3
$445K Sell
583
-7
-1% -$5.21K 0.03% 80
2025
Q2
$460K Sell
590
-5
-0.8% -$3.88K 0.03% 78
2025
Q1
$492K Buy
595
+8
+1% +$6.66K 0.04% 72
2024
Q4
$453K Sell
587
-8
-1% -$6.62K 0.03% 76
2024
Q3
$527K Sell
595
-76
-11% -$68.3K 0.04% 66
2024
Q2
$608K Buy
671
+8
+1% +$6.4K 0.05% 60
2024
Q1
$516K Sell
663
-45
-6% -$32K 0.04% 64
2023
Q4
$413K Sell
708
-5
-0.7% -$2.92K 0.04% 68
2023
Q3
$383K Buy
713
+3
+0.4% +$1.55K 0.04% 64
2023
Q2
$333K Sell
710
-3
-0.4% -$1.26K 0.03% 65
2023
Q1
$245K Sell
713
-43
-6% -$14.5K 0.02% 72
2022
Q4
$277K Buy
+756
New +$268K 0.03% 71

Other funds holding LLY

Rebalance's LLY Position: Q2 2026 in Review

Rebalance increased its Eli Lilly (LLY) stake by 0.89% in Q2 2026, buying an estimated $5.11K and bringing the position to 569 shares worth $682K. The position accounts for 0.04% of the portfolio, ranked #72.

Rebalance first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. 1,640 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Rebalance held 569 shares of Eli Lilly worth $682K as of Q2 2026.
  • Rebalance bought 5 Eli Lilly shares in Q2 2026, an estimated $5.11K.
  • Eli Lilly made up 0.04% of Rebalance's portfolio in Q2 2026, its #72 holding.
  • Rebalance first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • 1,640 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Rebalance's 13F filing for Q2 2026, filed 16 Jul 2026.